Edition:
India

People: Adverum Biotechnologies Inc (ADVM.OQ)

ADVM.OQ on NASDAQ Stock Exchange Global Market

20.46USD
6 Jul 2020
Change (% chg)

-- (--)
Prev Close
$20.46
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
516,568
52-wk High
$26.98
52-wk Low
$4.96

Carter, Eric 

Dr. Eric G. Carter M.D., Ph.D. serves as Independent Director of the Company. Dr. Carter served as Interim Chief Medical Officer of Alder BioPharmaceuticals, Inc. from April 2018 to January 2019. Dr. Carter served as senior vice president, chief medical officer, and global head of clinical and non-clinical development of Allergan, plc, a pharmaceutical company, from 2011 through a period of significant growth until its acquisition by Actavis Pharmaceuticals in 2015. Prior to Allergan, Dr. Carter served as chief scientific officer, head of research and development, and chief medical officer of King Pharmaceuticals from 2007 until the company was acquired by Pfizer, Inc. in 2011. From 2001 to 2007, he worked for GlaxoSmithKline plc, a pharmaceutical company, in positions of increasing responsibility within the global clinical development and medical affairs areas. After serving in academia at the University of North Carolina School of Medicine, the UCLA Fielding School of Public Health, and the University of California, Berkeley, Dr. Carter began his pharmaceutical career at Pharmacia Corporation, a pharmaceutical company, in 1993. He received a B.Sc. in Biochemistry from the University of London, a Ph.D. in Biochemistry from the University of Cambridge, and an M.D. from the University of Miami School of Medicine. Dr. Carter currently serves as the chair of the scientific advisory board at Bioniz Therapeutics. Dr. Carter has been chosen to serve on our Board due to his significant global experience in research and development in multiple therapeutic areas.

Basic Compensation

Total Annual Compensation, USD --
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 478,570
Fiscal Year Total, USD 478,570

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --